TOP TEN perturbations for 1552845_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552845_at
Selected probe(set): 219640_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552845_at (219640_at) across 6673 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 17 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-3.3362513
Number of Samples:9 / 10
Experimental ovarian tumor study 17
Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-3.0219593
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

ovarian tumor study 11 (borderline) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-3.0210152
Number of Samples:8 / 6
Experimental ovarian tumor study 11 (borderline)
Human microdissected tumor cells from the ovary of patients with low-malignant (borderline) tumors of the ovary.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

ovarian tumor study 11 (high grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-2.7950583
Number of Samples:22 / 6
Experimental ovarian tumor study 11 (high grade)
Human microdissected tumor cells from the ovary of patients with high grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-2.7917461
Number of Samples:11 / 6
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

ovarian tumor study 25 (serous ovarian cancer epithelium) / normal ovarian surface epithelium cell sample

Relative Expression (log2-ratio):-2.5077944
Number of Samples:12 / 12
Experimental ovarian tumor study 25 (serous ovarian cancer epithelium)
Laser capture micro-dissected serous ovarian cancer epithelium cells derived from female individuals with primary papillary serous adenocarcinoma of the ovary.
Control normal ovarian surface epithelium cell sample
Normal ovarian surface epithelium cell (OSE) samples isolated from female individuals by laser capture micro-dissection (LCM). Indication for removal of healthy ovaries were others than ovary cancer.

ovarian tumor study 13 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-2.360798
Number of Samples:18 / 12
Experimental ovarian tumor study 13
Human epithelial tumor cell samples from the ovary of patients with serous adenocarcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from healthy donors. Samples were derived by cell surface brushing.

rectal cancer study 2 (post; chemoradiotherapy) / rectal cancer study 2 (post; no therapy)

Relative Expression (log2-ratio):-1.8492794
Number of Samples:4 / 2
Experimental rectal cancer study 2 (post; chemoradiotherapy)
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.
Control rectal cancer study 2 (post; no therapy)
Tumor tissue samples obtained during a surgical resection from the rectum of untreated (no pre-operative treated) patients with rectal adenocarcinoma.Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.

rectal cancer study 2 (post; radiotherapy) / rectal cancer study 2 (post; no therapy)

Relative Expression (log2-ratio):-1.814825
Number of Samples:4 / 2
Experimental rectal cancer study 2 (post; radiotherapy)
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after treatment with short-course neoadjuvant radiotherapy (RT; 25Gy in 5 fractions). Samples were collected after 1 week of completing the therapy. Patients were selected for neoadjuvant RT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation, and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.
Control rectal cancer study 2 (post; no therapy)
Tumor tissue samples obtained during a surgical resection from the rectum of untreated (no pre-operative treated) patients with rectal adenocarcinoma.Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.

HCC study 9 (alcohol; HBV) / normal liver tissue

Relative Expression (log2-ratio):1.7673645
Number of Samples:3 / 10
Experimental HCC study 9 (alcohol; HBV)
Liver tissue biopsy sample from patients with alcohol abuse and Hepatitis B infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.